Dr Reddy's Laboratories launches generic version of Nexavar Tablets in US Markets

14 Jun 2022 , 10:55 AM

Dr. Reddy’s Laboratories Ltd. has announced the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar (sorafenib) Tablets in the U.S. market after receiving the approval from the U.S. Food and Drug Administration (USFDA).

“We are delighted to launch this crucial generic product, representing our continued commitment to bringing affordable generic medicines to market for patients,” commented Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories Inc.

Dr. Reddy’s Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.

Dr. Reddy’s has a vast portfolio of products and services including APIs, biosimilars and differentiated formulations, custom pharmaceutical services, and generics. Its majorly focuses on therapeutic areas such as gastrointestinal, diabetology, cardiovascular, pain management, oncology, and dermatology.

At around 10.54 AM, Dr Reddys Laboratories was trading at Rs4,268.40 per piece, up by Rs0.15 or 0% from its previous closing of Rs4,268.25 on the BSE. The scrip opened at Rs4,260 and has touched a high and low of Rs4,322.20 and Rs4,238.05 respectively.